Characteristics of HPV prevalence among women in Liaoning province, China

International Journal of Gynecology and Obstetrics

Volumn 109, Issue 2, 2010, Pages 105-109

  Sun, Zheng Rong ^a   Ji, Yao Hua ^a   Zhou, Wei Qiang ^a   Zhang, Shu Lan ^a   Jiang, Wei Guo ^a   Ruan, Qiang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cervical disease; HPV genotype; Prevalence

Indexed keywords

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER INVASION; CHINA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; WART VIRUS;

EID: 77950516283     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2009.11.026     Document Type: Article

References (24)

1. Van Tine B.A., Kappes J.C., Banerjee N.S., Knops J., Lai L., Steenbergen R.D., et al. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol 78 20 (2004) 11172-11186
2. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 24 (2001) 3106-3114
3. Muñoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
4. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1288 2 (1996) 55-78
5. Alam S., Bromberg-White J., McLaughlin-Drubin M., Sen E., Bodily J.M., and Meyers C. Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium. Anticancer Res 25 2A (2005) 765-777
6. Wu Y., Chen Y., Li L., Yu G., Zhang Y., and He Y. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol 35 3 (2006) 264-269
7. Liu J., Rose B., Huang X., Liao G., Carter J., Wu X., et al. Comparative analysis of characteristics of women with cervical cancer in highversus low-incidence regions. Gynecol Oncol 94 3 (2004) 803-810
8. Lai C.H., Chao A., Chang C.J., Chao F.Y., Huang H.J., Hsueh S., et al. Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 123 7 (2008) 1685-1692
9. Grisaru D., Avidor B., Niv J., Marmor S., Almog B., Leibowitz C., et al. Pilot study of prevalence of high-risk human papillomavirus genotypes in Israeli Jewish women referred for colposcopic examination. J Clin Microbiol 46 5 (2008) 1602-1604
10. Carozzi F., Bisanzi S., Sani C., Zappa M., Cecchini S., Ciatto S., et al. Agreement between the Amplicor HPV test and the Hybrid Capture 2 assay in the detection of high-risk human papillomavirus and biopsy-confirmed high-grade cervical disease. J Clin Microbiol 45 2 (2007) 364-369
11. Lo K.W., Wong Y.F., Chan M.K., Li J.C., Poon J.S., Wang V.W., et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 100 3 (2002) 327-331
12. Chan P.K., Lam C.W., Cheung T.H., Li W.W., Lo K.W., Chan M.Y., et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 94 16 (2002) 1249-1253
13. Schellekens M.C., Dijkman A., Aziz M.F., Siregar B., Cornain S., Kolkman-Uljee S., et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 93 1 (2004) 49-53
14. Sun C.A., Lai H.C., Chang C.C., Neih S., Yu C.P., and Chu T.Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 83 1 (2001) 95-99
15. Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92 6 (2000) 464-474
16. Lee S.A., Kang D., Seo S.S., Jeong J.K., Yoo K.Y., Jeon Y.T., et al. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett 198 2 (2003) 187-192
17. Chichareon S., Herrero R., Muñoz N., Bosch F.X., Jacobs M.V., Deacon J., et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 90 1 (1998) 50-57
18. Santos C., Muñoz N., Klug S., Almonte M., Guerrero I., Alvarez M., et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 85 7 (2001) 966-971
19. Rolón P.A., Smith J.S., Muñoz N., Klug S.J., Herrero R., Bosch X., et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 85 4 (2000) 486-491
20. Huang H.J., Huang S.L., Lin C.Y., Lin R.W., Chao F.Y., Chen M.Y., et al. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 14 4 (2004) 639-649
21. Naucler P., Da Costa F.M., Ljungberg O., Bugalho A., and Dillner J. Human papillomavirus genotypes in cervical cancers in Mozambique. J Gen Virol 85 Pt 8 (2004) 2189-2190
22. Huang L.W., Chao S.L., Chen P.H., and Chou H.P. Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 29 4 (2004) 271-276
23. Centurioni M.G., Puppo A., Merlo D.F., Pasciucco G., Cusimano E.R., Sirito R., et al. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis 5 27 (2005) 77
24. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255